In single dose acute toxicity studies in CD-I mice and CD rats, the median lethal dose (MLD) for zidovudine (ZDV) was >750 mg/kg after iv dosing and >3000 mg/kg after po administration (recommended human dose is 100 mg every 4 hr while awake). Because of the short half-life in rats (0.8 hr), dogs (1.0 hr), and monkeys (0.8 hr), the daily dose of ZDV in most studies was given in two equal portions approximately 6 hr apart Intravenous administration of ZDV was well tolerated in beagle dogs at dose levels up to 42.5 mg/kg bid for 2 weeks and in CD rats at dose levels up to 75 mg/kg bid for 4 weeks. In a 2-week dose rangefinding study in beagle dogs, cytostatic effects were noted at po dose levels of 62.5 to 250 mg/kg bid in certain tissues with rapid cell replication rates. In contrast, in 3-to 12-month oral toxicity studies in CD rats and cynomolgus monkeys, the principal toxicologic finding was reversible macrocytic normochromic anemia which occurred at 225-250 mg/kg bid in rats and 17.5-150 mg/ kg bid in monkeys. In the 12-month rat study, RBC was decreased at 25 and 75 mg/kg bid. In the 12-month monkey study WBC was slightly decreased at 150 mg/kg bid. o i
Zidovudine (ZDV), an antiretroviral agent active in vitro against the human immunodeficiency virus (HIV) is a thymidine analog in which the 3'-hydroxy (-OH) group has been replaced by an azido (-N 3 ) group. Cellular enzymes convert ZDV into ZDV-triphosphate which interferes with HIV RNA-dependent DNA polymerase (reverse transcriptase) and thus inhibits viral replication. ZDV-triphosphate also inhibits cellular a-DNA polymerase in vitro, but only at concentrations that are 100-fold higher than those needed to inhibit HIV reverse transcriptase.
ZDV was the first antiviral agent licensed for the treatment of acquired immunodeficiency syndrome (AIDS). In placebo-controlled studies in patients with AIDS or AUDS-related complex, ZDV treatment improved survival and decreased the number of opportunistic infections (Fischl et at, 1987 (Fischl et at, , 1990 . The principal side effects in these studies were macrocytic anemia and neutropenia.
Before a Phase I clinical trial of intravenously administered ZDV was conducted, the nonclinical toxicologic potential of intravenously administered ZDV was first assessed in mice, rats, and dogs. Subsequently, oral toxicology studies of varying duration were carried out in rats, mice, and monkeys.
In the early stages of ZDV development, since large amounts of a natural source thymidine were required to synthesize ZDV, its availability was very limited. Given the limited quantities of ZDV available for nonclinical testing and the urgent need for anti-HTV therapy, every effort was made to conserve the drug for use in the Phase I human trial. Therefore, preliminary dose range-finding experiments to aid in dose selection for formal toxicology studies were not conducted. Instead, the highest dose of ZDV used in the repeat dose intravenous toxicology studies was a multiple of the projected human dose ranging from approximately 6fold in dogs to 10-fold in rats. As larger amounts of the drug became available, repeat dose range-finding and formal oral toxicology studies were conducted in rats and monkeys.
Metabolism studies (Good et al, 1986 (Good et al, , 1989 Blum et at, 1988) revealed that the principal route of metabolism in humans was glucuronidation. Although the glucuronidation of ZDV in dogs, rats and mice was limited, in cynomolgus monkeys the extent of metabolism of ZDV to the glucuronide of ZDV (GZDV) was almost identical to that in humans. The extent of glucuronidation (expressed as a percentage of administered dose) in the species employed in the toxicology studies was as follows: rat and mouse, ~3%; dog, ~15%; monkey, ~60%. In comparison, in the human 65-80% of a dose is transformed to GZDV. Because of the short halflife in rats (0.8 hr), dogs (1.0 hr), and monkeys (0.8 hr), the daily dose of ZDV in these studies was given in two equal portions approximately 6 hr apart.
(maximum of 5-10 per cage). For the intravenous toxicity studies, ZDV was dissolved in 0.9% sterile saline and administered to 10 of each sex via the tail vein. The dose level selected, 750 mg/kg, was the highest practical dose that could be used based on drug solubility (15 mg/ml) and the maximum dose volume the animals could tolerate as an iv bolus (50 ml/kg). For the oral toxicity studies ZDV was suspended in 0.5% methylcellulose and administered at doses of 2500 and 3750 mg/kg to mice and 2500, 3750, and 5000 mg/kg to rats. In each study the animals were observed for signs of toxicity for 14 days after dosing and body weights were measured weekly. As there was only a single dose level and no mortalities in the acute iv studies, statistics were not required to calculate the iv median lethal dose (MLD). The oral MLD was calculated by the Probit Analysis procedure in the Statistical Analysis System (SAS Institute Inc., 1990) or by the method of Litchfield and Wilcoxon (1949) .
One-month intravenous toxicity study in rats. Four groups of 12 male and 12 female CD rats, 1 weighing from 176 to 310 g, were singly housed in suspended wire cages and were provided food 2 and water ad libitum. A solution of ZDV in 0.9% sterile saline (concentrations of 3.8 to 15 mg/ml) was administered rapidly via the tail vein, at doses of 0, 38, 75, and 150 mg/kg, once daily for 28 consecutive days. Three additional groups of 6 males and 6 females each were given the same doses and sacrificed on dose Day 13 in order to obtain blood for clinical pathology determinations. All rats were observed daily for pharmacotoxic signs and individual body weights and food consumption were measured weekly. Blood for hematologic (RBC, Hb, PCV, MCV, MCH, MCHC, RDW, WBC, Diff, Platelets) and clinical chemistry (Alk. Phos., BUN, CRE, Bili., Glu., K, Na, AST, ALT, Total Prot., Alb, Glob) determinations was collected from the tail vein before the start of dosing, at termination of satellite dose groups used only for obtaining blood samples on Day 13, at termination of the dosing period, and at the end of an 18-day drug-free recovery period. The eyes were examined by indirect ophthalmoscopy and slit-lamp biomicroscopy before treatment and at the end of the dosing and recovery periods. At the end of the dosing period, 8 males and 8 females from each group were necropsied after ether anesthesia. The remaining 4 males and 4 females in each group were necropsied at the end of the recovery penod. The following organs were weighed at necropsy: brain, liver, kidneys, testes, adrenals, thyroids/parathyroids, and pituitary. A wide variety of tissues were collected from all rats and fixed in 10% neutral buffered formalin. Tissues from all control and high dose rats were processed and examined by light microscopy.
Two-week intravenous toxicity study in dogs. Four groups of three male and three female young adult purpose-bred beagle dogs 3 were housed in individual stainless steel cages, fed a commercial feed, 4 and offered fresh tap water ad libitum. ZDV was dissolved in 0.9% sterile saline (concentrations of 1.9 to 7.5 mg/ml) via the cephalic vein at doses of 0, 10 75, 21.25, or 42.5 mg/kg bid at an infusion rate of 10 ml/min. The dogs were examined daily for pharmacotoxic signs and individual body weights and food consumption were measured weekly. Blood for hematologic (RBC, Hb, PCV, MCV, MCH, MCHC, RDW, WBC, Diff., Platelets) and clinical chemistry (Alk. Phos., BUN, CRE, Bill., Glu., K, Na, AST, ALT, Total Prot., Alb, Glob) determinations was collected from the jugular vein before dosing, on dose Days 6 and 14, and at the end of a 15-day drug-free recovery period. The eyes were examined by indirect ophthalmoscopy and slit-lamp biomicroscopy before the start of treatment and at the end of the dosing and recovery periods. Electrocardiographic examinations (leads I, II, III, aVR, aVL, aVF, rV 2 , MV 2 , MV<, and V l0 ) were carried out twice before the start of dosing, on dose Days 5 and 13, and at the end of the recovery period. Upon completion of dosing, 2 males and 2 females from each group were anesthetized with sodium pentobarbital, terminated, examined grossly. The remaining male and female in each group were necropsied at the end of the recovery period. The following organs were weighed at necropsy: brain, liver, kidneys, testes, adrenals, thyroids, and pituitary. A wide variety of tissues were taken from all dogs, fixed in 10% neutral buffered formalin, processed, and examined by light microscopy.
Two-week oral dose range-finding study in dogs. Four groups of one male and one female purpose-bred beagle dogs 3 were each given 0, 62.5, 125, or 250 mg/kg bid of ZDV po in gelatin capsules for 15 consecutive days. Clinical signs were monitored daily and body weights were measured weekly. Hematology (RBC, Hb, PCV, MCV, MCH, MCHC, RDW, WBC, Diff., Platelets) and clinical chemistry (Alk. Phos., BUN, CRE, Bili., Glu., K, Na, AST, ALT, Total ProL, Alb, Glob) parameters were assayed before the start and at the end of dosing. Drug plasma level analyses were done by HPLC on plasma obtained 30 mm after the first dose on dose Days 2 and 14 At the end of dosing, all dogs were anesthetized with sodium pentobarbital, sacrificed and examined grossly. Tissues were collected from all dogs, fixed in 10% neutral buffered formalin, processed, and examined by light microscopy.
Two-week oral dose range-finding study in monkeys. Four groups of one male and one female feral cynomolgus monkeys 3 were each given 0, 62.5, 125, or 250 mg/kg bid of ZDV po in 0.5% methylcellulose for 14 consecutive days. Clinical signs were monitored daily and body weights were measured weekly. Hematology (RBC, Hb, PCV, MCV, MCH, MCHC, RDW, WBC, Diff., Platelets) and clinical chemistry (Alk. Phos., BUN, CRE, Bih., Glu., K, Na, AST, ALT, Total Prot., Alb, Glob) parameters were assayed before the start and at the end of dosing. Drug plasma level analyses were done by HPLC on plasma obtained 30 min after the first dose on dose Days I and 13. At the end of dosing, all monkeys were anesthetized with sodium pentobarbital, terminated, and examined grossly. Tissues were collected from all animals, fixed in 10% neutral buffered formalin, processed, and examined by light microscopy.
Three-, 6-, and 12-month oral toxicity studies in rats. CD rats' weighing 170 to 320 g (3-month study), 161 to 232 g (6-month study), or 210 to 312 g (12-month study) were singly housed in suspended wire cages and provided food 2 and water ad libitum. In the 3-and 6-month studies, ZDV was given by gavage as a solution in distilled water to groups of 12 male and 12 female rats. Dose levels were 0, 28, 83.5, or 250 mg/kg bid in the 3-month study and 0, 25, 75, or 250 mg/kg bid in the 6-month study.
In the 12-month study, ZDV was given by gavage as a suspension in 0.5% methylcellulose to groups of 25 male and 25 female rats at doses of 0, 25, 75, or 225 mg/kg bid. Because of solubility limitations and the longer dosing period, methylcellulose was used in the 12-month study to reduce the required dose volume at 225 mg/kg bid. The use of methylcellulose was not thought to have altered the absorption of ZDV.
In each study, the rats were observed daily for pharmacotoxic signs and food consumption and individual body weights were measured weekly. Blood for hematology (RBC, Hb, PCV, MCV, MCH, MCHC, RDW, WBC, Diff., Platelets) and serum chemistry (Alk. Phos., BUN, CRE, Bili , Glu . K, Na, AST, ALT, Total Prot., Alb, Glob) analyses was collected before dosing, at intervals during the dosing period and at the end of the dosing and recovery periods. Unnalyses were carried out before the start and at the end of dosing in each study. The eyes were examined by indirect ophthalmoscopy and slit-lamp biomicroscopy before and at the end of dosing. In the 3-month study, blood for measurement of approximate peak drug plasma levels was collected 30 nun after the first dose on Days 2 and 90 from 3 rats per sex per group from separate (satellite) groups at each dose terminated specifically for the purpose of blood collection. Similarly, blood for determination of approximate peak drug plasma levels was obtained 30 min after the last dose on Days 2 and 177 in the 6-month study.
' Charles River Research Primates Corp., Port Washington, NY. Based on data from the latter study it was drought that a more accurate measure of approximate peak plasma level would be obtained by later sampling. Therefore, drug plasma analyses were performed on plasma obtained 1 hr after the last dose on Days 2, 189, and 365 in the 12-month study. At the end of dosing, 7 to 8 males and females per group in the 3and 6-month studies, or 10 to 18 males and females per group in the 12month study, were necropsied. The following organs were weighted at necropsy in all three studies: brain, liver, kidneys, and testes. The following additional organs were weighed in the 12-month study: heart, thyroids/ parathyroids, spleen, adrenals, prostate, ovaries, and salivary glands. Semen analyses (count, motility, and morphology) were performed on each surviving male just before termination after 6 and 12 months of dosing. Sperm morphology was evaluated by Environmental Health and Research Testing (Lexington, KY). A wide variety of tissues were taken from all animals at necropsy and fixed in 10% neutral buffered formalin. The tissues from control and high dose rats were processed and examined by light microscopy.
Drug-free recovery periods were included in each study. The last dose day/first recovery day was 91/+1, 184/+1, and 373/+1 for the 3-, 6-, and 12-month studies, respectively. The duration of the recovery periods were 18, 57, and 70 days in the 3-, 6-, and 12-month studies, respectively. At the termination of the recovery period, four males and four females in each group in the 3-and 6-month studies, and five males and five females in each group in the 12-month study were necropsied.
Three-, 6-, and 12-month oral toxicity studies in monkeys. Groups of four male and four female 3 (3-month study), five male and five female 6 (6month study), or six male and six female 7 (12-month study) cynomolgus monkeys were housed individually in stainless steel cages, fed commercial feed, 8 and offered fresh tap water ad libitum. Doses of ZDV were 0, 17 5, 50, or 150 mg/kg bid given by gavage as a suspension in 0.5% methylcellulose. The monkeys were observed daily for pharmacotoxic signs and individual body weights were recorded weekly. Appetite was assessed daily. Blood for hematology (RBC, Hb, PCV, MCV, MCH, MCHC, RDW, WBC, Diff., Platelets) and serum chemistry (Alk. Phos., BUN, CRE, Bili., Glu., K, Na, AST, ALT, Total ProL, Alb, Glob) analyses was collected from the femoral vein before dosing began and at intervals throughout the dosing and recovery periods. Urinalyses were carried out before the start and at the end of dosing in each study. Vitamin B, 2 levels were assayed at intervals in the 12-month study. Blood for measurement of approximate peak drug plasma levels was collected from the femoral vein as follows: 30 min after the first dose on dose Days 2 and 87 in the 3-month study and on Days 1 and 180 in the 6-month study and 30 min after the second dose on Days 2, 181, and 363 in the 12-month study. Eyes were examined by indirect ophthalmoscopy and slit-lamp biomicroscopy before treatment began and at the end of the dosing and recovery periods. Electrocardiograph^ examinations (leads I, II, III, aVR, aVL, aVF, MV,, MV 2 , MV 3 , and V lo ) were carried out before treatment began, at intervals during the dosing period and at the end of the treatment and recovery periods in all three studies. In the 3-month study, testicular measurements (smallest and largest diameter of the elliptical shape) were recorded before dosing started and at the end of the dosing and recovery periods. In the 6-and 12-month studies, multiple semen samples were obtained by electroejaculation, from each male before dosing began and near the end of the treatment period. It should be noted, however, that it was not possible to obtain semen samples from all males at each sampling time. Sperm count, motility, live/dead ratio, and morphology were assessed in these samples. In addition, menstrual cycle evaluations were conducted in the 6-month study by daily examination of vaginal Highest practical dose based on drug solubility (15 mg/ml) and maximum dose volume animals could tolerate as an iv bolus (50 ml/kg).
smears. At the termination of dosing, three males and three females (3-and 6-month studies) or four males and four females (12-month study) from each group were necropsied. In all three studies the following organs were weighed: brain, liver, kidneys, and testes. The following additional organs were weighed in the 6-and 12-month studies: epididymides, heart, lung, ovaries, adrenals, pituitary, prostate, spleen, thymus, diyroids, uterus, and salivary glands. A wide variety of tissues were taken from all animals, fixed in 10% neutral buffered formalin, processed, and examined by light microscopy.
Drug-free recovery periods were included in each study. The last dose day/first recovery day was 91/+1, 184/+1, and 366/+1 for the 3-, 6-, and 12-month studies, respectively. The duration of the recovery penods were 39, 46, and 35 days in the 3-, 6-, and 12-month studies, respectively. At the termination of the recovery period, one male and one female in each group in the 3-month study and two males and two females in the 6-and 12-month studies were necropsied and organs were weighed. A wide variety of tissues were taken from each animal, fixed in 10% neutral buffered formalin, processed, and examined by light microscopy.
Statistical methods. Hematology parameters were evaluated using a one-way ANOVA (Winer, 1971 ) followed by Dunnett's test (Dunnett, 1955 (Dunnett, , 1964 to compare each treated group mean with that of the control group. All computations were performed by SAS (SAS Institute Inc., 1990).
RESULTS

Acute Toxicity Studies in Mice and Rats
Median lethal dose (MLD) values are shown in Table 1 . In mice given intravenous ZDV, one female mouse died without premonitory signs after receiving 487 mg/kg of the total dose of 750 mg/kg. No deaths occurred in rats treated iv. Shortly after dosing, decreased activity and ptosis were noted in the majority of mice and rats. Labored breathing was also observed in both species. Clonic convulsions were seen in a single female mouse 3 min after drug administration. Animals returned to normal within 2 1/2 hr after dosing.
No deaths occurred on the day of dosing in mice or rats given 2500 mg/kg po. In animals given 3750 mg/kg, 3 of 10 mice and 3 of 10 rats died on the day of dosing, as did 4-5 rats of each sex given 5000 mg/kg. Delayed deaths were seen on postdose Day 1 in 7 of 10 rats given 3750 or 5000 mg/kg and on postdose Days 1 (4 of 10) and 2 (2 of 10) in mice given 3750 mg/kg. Decreased activity and ptosis were observed in both rats and mice given 3750 mg/kg.
One-Month Intravenous Toxicity Study in Rats
No drug-related clinical signs or deaths occurred. Body weight gains and food consumption were comparable for control and treated rats during the study and there were no drug-related changes in hematologic, clinical chemistry, or ophthalmologic parameters. At necropsy, absolute and relative organ weights were comparable in control and treated groups and no drug-related gross or histopathologic changes were seen.
Two-Week Intravenous Toxicity Study in Dogs
Emesis was the only treatment-related clinical sign, occurring once in a female given 10.75 mg/kg bid and once in a male and female given 42.5 mg/kg bid. Body weight gain and food consumption were not altered by treatment, and no drug-related changes in hematology, clinical chemistry, ophthalmology, or electrocardiographic parameters were observed. Organ weights were comparable between the control and treated groups at necropsy and there were no treatment-related gross or histopathologic changes.
Two-Week Oral Dose Range-Finding Study in Dogs
Severe weight loss and dehydration were observed in the female given 250 mg/kg bid and it was terminated for humane reasons on dose Day 14. The animal had previously shown emesis and diarrhea with blood in the vomitus and feces. Vomiting, with blood, was also noted in the 250 mg/ kg bid male. Body weight was unaffected in the other dose groups. No treatment-related changes in clinical chemistry parameters were seen in any dog given ZDV. Marked thrombocytopenia was observed in all treated groups at the end of dosing. Dogs given 250 mg/kg bid were the most severely affected and showed leukopenia as well. With the exception of the group given 250 mg/kg bid, slight to mild reductions in total erythrocyte count (RBC), hemoglobin (Hb), and packed cell volume (PCV) were seen in each treated group. The absence of change in these parameters in the group given 250 mg/kg bid was thought to have been due to dehydration. Hematologic data at the termination of this study are shown in Table 2 . Histopathologically, cytostatic effects were seen in some tissues with rapid cell-replication rates. These included: (a) maturational arrest enteritis of the small intestine in dogs given 250 mg/kg bid, characterized by inflammatory cell infiltration and the blunting and fusing of villi; (b) nondose-related, slight to moderate lymphoid depletion of the thymus, lymph nodes, and Peyer's patches at all doses; and (c) mild to marked, dose-related bone marrow hypocellularity in all treated groups. Plasma concentrations of ZDV 15 min after the first dose on dose Day 14 were highly variable and averaged 36 /xg/ml at 62.5 mg/kg bid, 12 fig/ ml at 125 mg/kg bid, and 3.9 Mg/ml at 250 mg/kg bid.
Two-Week Oral Dose Range-Finding Study in Monkeys
The male given 250 mg/kg bid often vomited shortly after treatment, but no change in body weight occurred in this or any other monkey. There was a very slight reduction in Hb and PCV in one animal given 62.5 mg/kg bid and in both monkeys given 250 mg/kg bid. Hematologic data at the end of the study are illustrated in Table 2 . No changes were seen in total or differential leukocyte count (WBC) or in clinical chemistry parameters that were considered to be related to drug treatment, no deaths occurred, and no drug-related gross or histopathologic changes were seen at the end of the study.
Since the metabolism of ZDV in monkeys was found to be almost identical to the human, subsequent preclinical nonrodent toxicology studies were conducted in Cynomolgous monkeys.
Three-, 6~, and 12-Month Oral Toxicity Studies in Rats
Treatment-related staining of the abdominal and anogenital body hair was seen in males given 250 mg/kg bid in the 3-month study and in both sexes given 250 mg/kg bid in the 6-month study. During the 12-month study, postdose salivation (attributed to the bitter taste of ZDV) was the only sign observed. It occurred in the majority of animals given 225 mg/kg bid during the first 2 weeks of dosing and in a minority of these rats during the remainder of the study. Body weight, food consumption, clinical chemistry, and urinalysis and ophthalmologic parameters were unaffected by treatment in any of the studies. No drug-related changes were noted in semen evaluations performed at the termination of the 6-and 12-month studies. No changes in organ weight, no gross pathologic or histopathologic changes, and no treatment-related deaths were seen in any of the studies.
Statistically significant (p =£ 0.05) reductions in RBC and increased mean corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH) were observed in each study, principally in rats given 75 to 250 mg/kg bid of ZDV. Minor, statistically significant changes were also seen in some parameters in animals given 25 mg/kg bid. Changes in RBC were noted as early as dose Day 16, while the elevations in MCV and MCH did not occur until dose Day 30. In some treatment groups, red cell distribution width (RDW) was also increased. The hematology data at term for each study are shown in Tables 3, 4, and 5. The altered parameters returned to levels comparable to control values by recovery Day 56 or 63 for the 6-and 12-month studies, respectively. Although some statistically significant changes were seen in mean corpuscular hemoglobin concentration (MCHC) and WBC, none of these findings were considered to be the result of drug treatment. No treatment-related alterations in platelet counts occurred. Reticulocyte counts were slightly increased in males at all doses in the 6-month study and in both sexes at all doses in the 12-month study. As shown in Table 3 , 10.8 (2.6) 6.2(1.1) 8.1 (2.1) 1.0(0.9) 12.0 (1.7) 13.0 (11.7) 15.8 (6.5) 9.3 (0.3) RBC (10*/ml) 6.6 (0.7) 5.7 (0.9) 5.7 (0.2) 7.0(1.6) 6.4 (0.6) 5.7 (0.3) 5.8 (0.1) 6.1 (0.7) HGB (g/dl) 15.5(1.1) 13.5 (2.9) 13.7 (0. (243) the severity of the anemia after 6 months of dosing with ZDV was similar to that noted after 12 months. As presented in Table 6 , mean ZDV plasma concentrations increased with dose at all time points in all three studies. While drug plasma levels at term in the 6-month study were higher than those on dose Day 2 (data not shown), the concentrations seen at any dose level on Day 365 of the 12-month study did not differ significantly from the levels seen on Days 2 or 189.
Three-, 6-, and 12-Month Oral Toxicity Studies in Monkeys
ZDV treatment resulted in a reversible, dose-related macrocytic normochromic anemia characterized by statistically (p s£ 0.05) and biologically significant reductions in RBC, Hb, and HCT and elevated MCV and MCH in monkeys given 17.5, 50, or 150 mg/kg bid. The hematology data at term for each study are illustrated in Tables 7, 8, and 9. While there were some MCHC values noted to be statistically different from control values, these changes were not thought to be meaningful. Reticulocyte counts were unaltered in these studies. These changes were observed as early as dose Day 15. When treatment was halted there was a return to normal values by postdose Days 30 to 43. As was noted in rats, reductions in RBC, Hb, and HCT occurred first followed by increases in MCV and MCH. In the 3month study, treatment had no biologically meaningful effect 9(1.8)  3.0 (0.3)   3.0(1.8)  2.8 (0.9)   2.3 (0.9)  4.2(1,3) 7 (0 6)  13.5 (0.6)   15 2 (0.9)  13.7 (0.4)   14.7 (0.8)  13.8(0.4)   15.9(1.0)*  16.8(1.2) ' on total or differential WBC counts, whereas from day 10 dosing in the 12-month study, WBC and segmented neutroin the 6-month study there was a slight reduction in WBC phil counts were slightly lower in all treated groups at several in males given 150 mg/kg bid. Although nonstatistically intervals, but especially in monkeys given 150 mg/kg bid. significant changes were seen in WBC at the termination of In some animals in all treated groups in all three studies sporadic thrombocytosis was noted at intervals during treatment. Bone marrow evaluation of smears and histologic sections in the 6-month study revealed hypercellularity at all dose levels. In animals given 50 and 150 mg/kg bid there was a progressive retardation in maturation of all cell lines, especially the erythroid elements. At the highest dose this was characterized by an increase in basophilic normoblasts and erythroblasts while mature myeloid elements were somewhat reduced in number. In the 12-month study, mini-mal to moderate macrocytic change was seen in erythrocytes and erythroblasts and there was also a slight increase in Howell-Jolly bodies in treated groups. In recovery animals in both the 6-and the 12-month studies, no meaningful residual effects were noted in the bone marrow. There were no meaningful changes in clinical signs, body weight or appetite, clinical chemistry, urinalyses, or ophthalmologic and electrocardiographic examinations in the three studies.
RDW (*)
14.
In the 6-month study, treatment had no effect on menses.
No drug-related changes were seen in semen evaluations conducted during the 6-and 12-month studies. In the latter study, serum vitamin B 12 levels were unaltered in animals given 17.5 or 50 mg/kg bid, but were elevated in monkeys given 150 mg/kg bid. No drug-related organ weight, gross pathologic, or histopathologic changes (other than those mentioned above for bone marrow cytology) were noted in any of these studies. Mean ZDV plasma levels, as shown in Table 10 , increased with dose in all three studies. In the 3and 6-month studies, GZDV levels were higher than the levels of parent drug at each sampling point. GZDV levels were not measured in the 12-month study.
DISCUSSION
Acute single-dose toxicity studies in rats and mice with ZDV revealed the MLD to be greater than 750 (iv) and 3000 mg/kg (po) in both species. ZDV was well tolerated when given iv to rats 4 weeks and dogs for 2 weeks. 11.9(4 3) 9.9 (2 4) 11.4(3.5) 8.0 (3.2) 9.0 (3 7) 5.6 (2.7) 4 9(1.4)* 5.5 (2.9) 11.6 (2 0) 11.2(3.8) In dogs given 62.5-250 mg/kg bid of ZDV po for 14 days, cytostatic effects were seen in certain tissues with rapid cell replication rates (bone marrow, gastrointestinal epithelium, lymphoid tissue). The clinical signs in these animals (diarrhea, anemia, leukopenia, thrombocytopenia, and at the highest dose, death) were considered to be secondary to cytostatic effects seen in these tissues. Cytostatic effects were not seen when identical doses were given to monkeys in a 2-week oral dose range-finding study. Similarly, doses of 225-250 mg/kg bid did not induce cytostatic effects in 3-, 6-, and 12-month studies in rats. Why the dog is more sensitive to ZDV than the monkey or rat is not known. It has been our experience, however, that dogs are more sensitive in general to the effects of nucleoside analogs than some other species. For example, high doses of acyclovir, the anti-herpes nucleoside analog, caused toxic effects in dogs similar to those seen with ZDV (Tucker et al., 1983) . Toxicity with acyclovir was less severe in rodents. It should also be noted that dogs are more sensitive to the effects of ionizing radiation than are rats or monkeys. Bond et al. (1969) showed that the LDso for acute whole body radiation was two-to threefold greater for rats and monkeys than for dogs. Species differences in metabolism or pharmacokinetics are not thought to have influenced toxicity. As has been shown, a smaller percentage of a dose of ZDV is metabolized to GZDV in dogs than in monkeys. At a given dose level, therefore, plasma concentrations of ZDV would be expected to be higher in the dog than the monkey. One might be tempted to conclude from this that the toxicity in the dog was related to higher plasma levels of parent drug. However, an even smaller percentage of a dose of ZDV is metabolized to GZDV in the rat, but the severity of drug-related changes seen in this species is less than that observed in dogs or monkeys. Differences in toxicity would also not appear to be related to pharmacokinetics, as the half-life of elimination is similar in rats (0.8 hr), dogs (1.0 hr), and monkeys (0.8 hr). It appears, therefore, that differences in the degree of toxicity seen in the species used in these studies resulted from varying species sensitivity to ZDV.
Reversible macrocytic normochromic anemia was seen in rats and monkeys treated with ZDV po for periods of up to 12-months. In monkeys, ZDV administration was also associated with sporadic thrombocytosis and leukopenia. Neither of these effects were seen in rats. In both species, reductions in RBC were seen as early as 2 weeks after the start of treatment, whereas changes in MCV and MCH were not generally seen before 4 weeks of treatment had been completed. In the 12-month studies in rats and monkeys, it was evident that the severity of the anemia peaked after 6 months of treatment with ZDV and that no significant changes in the degree of anemia occurred in the last 6 months of the dosing period. Similarly, when the hematologic data at the termination of the 3-, 6-, and 12-month studies were compared, there was no significant difference in the severity of the anemia seen after 6 months of dosing compared to that seen after 12 months of dosing. Thus, treatment beyond 8 (1.9)  12.1 (4.6) 8 6 months neither increased the severity of the anemia nor resulted in any new toxicities. Upon cessation of dosing, reversal of changes in RBC, PCV, and Hb were noted first, followed by a return to normal for MCV and MCH. All hematologic parameters were normal after 63 days.
Hematologic toxicity of ZDV in rats was noted by Ayers (1988) and Thompson et al. (1991) , ZDV has also been shown to induce macrocytic anemia in mice (Ayers, unpublished observations; Thompson et al., 1991) . Although the anemia is macrocytic in both rats and in humans, there is no evidence that disorders of vitamin Bi 2 or folic acid metabolism are responsible for the macrocytosis. This is supported by data from the 12-month monkey study with ZDV in which vitamin B )2 levels were either normal (17.5 and 50 mg/kg bid) or elevated (150 mg/kg bid). The underlying mechanism of the ZDV-induced anemia appears to be related to the suppressive effect of ZDV on bone marrow progenitor cells. Johnson et al. (1988) studied the effect of ZDV on erythroid myeloid bone marrow progenitor development and showed that the drug suppresses BFU-E and CFU-GM development in vitro, even at the minimum concentrations inhibitory to HIV. They also demonstrated that progenitor cells derived from HlV-infected individuals appeared to be as sensitive to the inhibitory effects of ZDV as progenitor cells derived from healthy, HIV-negative subjects. In contrast, Ganser et al. (1989) found that while ZDV inhibited human bone marrow colony growth, the pluripotent colonies, CFU-GEMM and BFU-E, derived from AIDS patients were more sensitive to the effects of ZDV and suggested that this might explain the high rate of anemia seen in AIDS patients treated with higher dose levels of ZDV. Dainiak and his colleagues (1988) also demonstrated that ZDV impairs the proliferation of human hemapoietic progenitors and that erythroid precursors are particularly sensitive. Abraham et al. (1989) demonstrated that ZDV suppresses human and mouse bone marrow colony growth (CFU-E, BFU-E, CFU-GM, and CFU-Fb) and that bone marrow colonies from mice were more sensitive than those from humans. They further showed that some of the inhibitory effects of ZDV could be overcome by the addition of hemin to the cultures. Others have confirmed these observations and have also shown that heme synthesis is impaired in ZDV-treated animals (Lutton et al., 1990) . They demonstrated that the rate-limiting enzyme in heme biosynthesis, alpha-aminolevulinic acid synthase (ALAS), is suppressed by treatment with ZDV.
The magnitude of the decreases seen in WBC and neutrophil counts in monkeys given 150 mg/kg bid of ZDV for 6 months or 1 year was generally small and not thought to be biologically significant. Luster et al. has reported that there were no changes in immune function, including natural killer cell function, cytotoxic T-lymphocyte activity or macrophage antitumor activity in mice given doses of ZDV of up to 600 mg/kg/day.
Thrombocytosis was observed at intervals at all dose levels in each of the monkey studies and increases in platelet count have also been noted in humans treated with ZDV (Rachlis, 1990) .
Exposure of test animals to ZDV in the toxicity studies exaggerated the plasma levels required for therapeutic efficacy in humans. Mean peak plasma concentrations for ZDV were in the range of 11 to 77 ^glm\ for rats and 2 to 22 /j,g/ ml for monkeys approximately 30 min to 1 hr after the second dose at termination of the 12-month studies. These concentrations are many multiples of the IDso concentrations of ZDV (0.001 ^g/ml) required to inhibit HIV in vitro (Balzarini et al., 1988) and are also significantly higher than the mean steady-state concentrations observed at the recommended daily dose of 100 mg every 4 hr (0.62 /zg/ml [Medical Economics Company, 1993] ).
The nonclinical studies described here demonstrate that the principal toxicologic effect resulting from chronic treat-ment with ZDV was macrocytic anemia. The anemia, which was similar in presentation to that seen in humans treated with ZDV, was readily reversible upon cessation of treatment.
